BioCentury

8:00 AM GMT, Nov 19, 2001
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

The Enbrel space

It's no secret that Immunex Corp. can't make enough of its Enbrel etanercept rheumatoid arthritis drug to meet demand. With every passing day, there is the potential that new patients will start taking the one competing anti-TNF drug, Johnson & Johnson's Remicade anti-TNF chimeric monoclonal antibody, which is approved for both RA and Crohn's disease.

IMNX also faces the possibility that it won't

Read the full 638 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.